AR080221A1 - IMMUNOCOMPATIBLE AMNIOTIC MEMBRANE PRODUCTS - Google Patents

IMMUNOCOMPATIBLE AMNIOTIC MEMBRANE PRODUCTS

Info

Publication number
AR080221A1
AR080221A1 ARP110100508A ARP110100508A AR080221A1 AR 080221 A1 AR080221 A1 AR 080221A1 AR P110100508 A ARP110100508 A AR P110100508A AR P110100508 A ARP110100508 A AR P110100508A AR 080221 A1 AR080221 A1 AR 080221A1
Authority
AR
Argentina
Prior art keywords
cells
placenta
cryopreservant
minute
minutes
Prior art date
Application number
ARP110100508A
Other languages
Spanish (es)
Inventor
Jennifer Michelle Marconi
Timothy Jansen
Samson Tom
Alla Danilkovitch
Dana Yoo
Jin-Qiang Kuang
Original Assignee
Osiris Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osiris Therapeutics Inc filed Critical Osiris Therapeutics Inc
Publication of AR080221A1 publication Critical patent/AR080221A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/125—Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/02—Coculture with; Conditioned medium produced by embryonic cells
    • C12N2502/025—Coculture with; Conditioned medium produced by embryonic cells extra-embryonic cells, e.g. amniotic epithelium, placental cells, Wharton's jelly

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Wood Science & Technology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Genetics & Genomics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)

Abstract

Productos placentarios que comprenden una membrana amniotica inmunocompatible. Estos productos placentarios pueden criopreservarse y contienen céluIas terapéuticas viables una vez descongelados. Los productos placentarios de la presente son utiles para promover la cicatrizacion. Reivindicacion 1: Un método para manufacturar un producto placentario, caracterizado porque comprende los siguientes pasos: a. obtener una placenta; b. eliminar selectivamente una porcion sustancial uno o más tipos de células inmunogénicas de la membrana amniotica, donde los uno o más tipos de células inmunogénicas comprenden los macrofagos CD14+ funcionales; y el paso de eliminacion selectiva conserva la viabilidad de una porcion sustancial de células terapéuticas nativas seleccionadas entre las MSC, los fibroblastos, las células epiteliales o una combinacion las anteriores; c. criopreservar la membrana amniotica en un medio de criopreservacion; y d. opcionalmente, eliminar sustancialmente la totalidad del tejido vascularizado o de las células inmunogénicas derivadas del tejido vascularizado de la placenta o de la membrana amniotica correspondiente. Reivindicacion 2: El método de la reivindicacion 1 caracterizado porque dicho paso de eliminacion comprende eliminar los trofoblastos de la membrana corionica y retener la membrana corionica. Reivindicacion 4: El método de la reivindicacion 1, caracterizado porque dicho paso de eliminacion comprende exterminar o inactivar selectivamente los macrofagos CD14+ funcionales. Reivindicacion 5: El método de la reivindicacion 4, caracterizado porque dicho paso de eliminacion comprende refrigerar la placenta durante un período de tiempo determinado antes del paso de criopreservacion. Reivindicacion 8: El método de la reivindicacion 5, caracterizado porque dicho período de tiempo es de al menos aproximadamente 10 minutos, aproximadamente 20 minutos, aproximadamente 30 minutos, aproximadamente 40 minutos o aproximadamente 50 minutos. Reivindicacion 10: El método de cualquiera de las reivindicaciones 5-9, caracterizado porque la refrigeracion comprende incubar la placenta durante dicho período de tiempo a una temperatura de entre aproximadamente -10°C y aproximadamente 15°C, o de aproximadamente 2°-8°C. Reivindicacion 11: El método de la reivindicacion 4, caracterizado porque dicho paso de eliminacion comprende tratar la placenta con un anticuerpo anti-TNF-alfa. Reivindicacion 13: El método de cualquiera de las reivindicaciones precedentes, caracterizado porque el paso de criopreservacion comprende reducir la temperatura a una velocidad menor que aproximadamente 10°C/minuto, aproximadamente 5°C/minuto, aproximadamente 3°C/minuto, aproximadamente 2°C/minuto o aproximadamente 1°C/minuto. Reivindicacion 15: El método de cualquiera de las reivindicaciones 1-12, caracterizado porque el criopreservante comprende un criopreservante que puede penetrar en las células, un criopreservante que no puede penetrar en las células o una combinacion de éstos, donde opcionalmente el criopreservante que puede penetrar en las células comprende: a. DMSO; o b. DMSO en una cantidad mayoritaria. Reivindicacion 17: El método de la reivindicacion 15, caracterizado porque el criopreservante que puede penetrar en las células comprende DMSO en una proporcion de entre aproximadamente 2% y aproximadamente 20%, entre aproximadamente 5% y aproximadamente 20%, entre aproximadamente 5% y aproximadamente 15% o entre aproximadamente 7% y aproximadamente 13%. Reivindicacion 18: El método de la reivindicacion 15, caracterizado porque el medio de criopreservacion también comprende albumina, donde opcionalmente la albumina es HSA. Reivindicacion 25: El método de cualquiera de las reivindicaciones 1-12, caracterizado porque el método comprende retener la capa basal, la capa compacta, la capa de fibroblastos y la capa esponjosa de la membrana amniotica. Reivindicacion 26: El método de la reivindicacion 25, caracterizado porque entre al menos aproximadamente 15,9% y aproximadamente 100%, entre aproximadamente 25% y aproximadamente 100%, entre aproximadamente 35% y aproximadamente 100%, entre aproximadamente 50% y aproximadamente 100%, entre aproximadamente 75% y aproximadamente 100%, entre aproximadamente 90% y aproximadamente 100%, entre aproximadamente 95% y aproximadamente 100% o sustancialmente la totalidad de las células del epitelio amniotico no son eliminadas de la placenta.Placental products comprising an immunocompatible amniotic membrane. These placental products can be cryopreserved and contain viable therapeutic cells once thawed. The placental products of the present are useful to promote healing. Claim 1: A method of manufacturing a placental product, characterized in that it comprises the following steps: a. get a placenta; b. selectively remove a substantial portion of one or more types of immunogenic cells from the amniotic membrane, where the one or more types of immunogenic cells comprise the functional CD14 + macrophages; and the selective elimination step preserves the viability of a substantial portion of native therapeutic cells selected from the MSCs, fibroblasts, epithelial cells or a combination of the foregoing; C. cryopreserve the amniotic membrane in a cryopreservation medium; and d. optionally, substantially eliminate all of the vascularized tissue or of the immunogenic cells derived from the vascularized tissue of the placenta or the corresponding amniotic membrane. Claim 2: The method of claim 1 characterized in that said elimination step comprises removing the trophoblasts from the chorionic membrane and retaining the chorionic membrane. Claim 4: The method of claim 1, characterized in that said elimination step comprises selectively killing or inactivating the functional CD14 + macrophages. Claim 5: The method of claim 4, characterized in that said elimination step comprises cooling the placenta for a certain period of time before the cryopreservation step. Claim 8: The method of claim 5, characterized in that said period of time is at least about 10 minutes, about 20 minutes, about 30 minutes, about 40 minutes or about 50 minutes. Claim 10: The method of any of claims 5-9, characterized in that the cooling comprises incubating the placenta during said period of time at a temperature between about -10 ° C and about 15 ° C, or about 2 ° -8 ° C. Claim 11: The method of claim 4, characterized in that said elimination step comprises treating the placenta with an anti-TNF-alpha antibody. Claim 13: The method of any of the preceding claims, characterized in that the cryopreservation step comprises reducing the temperature at a rate less than about 10 ° C / minute, about 5 ° C / minute, about 3 ° C / minute, about 2 ° C / minute or approximately 1 ° C / minute. Claim 15: The method of any of claims 1-12, characterized in that the cryopreservant comprises a cryopreservant that can penetrate the cells, a cryopreservant that cannot penetrate the cells or a combination thereof, where optionally the cryopreservant that can penetrate in the cells it comprises: a. DMSO; or b. DMSO in a majority amount. Claim 17: The method of claim 15, characterized in that the cryopreservant that can penetrate the cells comprises DMSO in a proportion of between about 2% and about 20%, between about 5% and about 20%, between about 5% and about 15% or between about 7% and about 13%. Claim 18: The method of claim 15, characterized in that the cryopreservation medium also comprises albumin, where the albumin is optionally HSA. Claim 25: The method of any of claims 1-12, characterized in that the method comprises retaining the basal layer, the compact layer, the fibroblast layer and the spongy layer of the amniotic membrane. Claim 26: The method of claim 25, characterized in that between at least about 15.9% and about 100%, between about 25% and about 100%, between about 35% and about 100%, between about 50% and about 100 %, between about 75% and about 100%, between about 90% and about 100%, between about 95% and about 100% or substantially all of the amniotic epithelial cells are not removed from the placenta.

ARP110100508A 2010-02-18 2011-02-18 IMMUNOCOMPATIBLE AMNIOTIC MEMBRANE PRODUCTS AR080221A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33846410P 2010-02-18 2010-02-18
US33848910P 2010-02-18 2010-02-18
US36956210P 2010-07-30 2010-07-30

Publications (1)

Publication Number Publication Date
AR080221A1 true AR080221A1 (en) 2012-03-21

Family

ID=44476694

Family Applications (6)

Application Number Title Priority Date Filing Date
ARP110100510A AR080223A1 (en) 2010-02-18 2011-02-18 THERAPEUTIC PRODUCTS THAT INCLUDE VITALIZED PLACENTARY DISPERSIONS
ARP110100505A AR080218A1 (en) 2010-02-18 2011-02-18 IMMUNOCOMPATIBLE CORIONIC MEMBRANE PRODUCTS
ARP110100506A AR080219A1 (en) 2010-02-18 2011-02-18 IMMUNOCOMPATIBLE CORIONIC MEMBRANE PRODUCTS
ARP110100507A AR080220A1 (en) 2010-02-18 2011-02-18 IMMUNOCOMPATIBLE AMNIOTIC MEMBRANE PRODUCTS
ARP110100509A AR080222A1 (en) 2010-02-18 2011-02-18 THERAPEUTIC PRODUCTS THAT INCLUDE VITALIZED PLACENTARY DISPERSIONS
ARP110100508A AR080221A1 (en) 2010-02-18 2011-02-18 IMMUNOCOMPATIBLE AMNIOTIC MEMBRANE PRODUCTS

Family Applications Before (5)

Application Number Title Priority Date Filing Date
ARP110100510A AR080223A1 (en) 2010-02-18 2011-02-18 THERAPEUTIC PRODUCTS THAT INCLUDE VITALIZED PLACENTARY DISPERSIONS
ARP110100505A AR080218A1 (en) 2010-02-18 2011-02-18 IMMUNOCOMPATIBLE CORIONIC MEMBRANE PRODUCTS
ARP110100506A AR080219A1 (en) 2010-02-18 2011-02-18 IMMUNOCOMPATIBLE CORIONIC MEMBRANE PRODUCTS
ARP110100507A AR080220A1 (en) 2010-02-18 2011-02-18 IMMUNOCOMPATIBLE AMNIOTIC MEMBRANE PRODUCTS
ARP110100509A AR080222A1 (en) 2010-02-18 2011-02-18 THERAPEUTIC PRODUCTS THAT INCLUDE VITALIZED PLACENTARY DISPERSIONS

Country Status (6)

Country Link
US (28) US20110212064A1 (en)
EP (10) EP2536823B1 (en)
AR (6) AR080223A1 (en)
CA (6) CA2790436A1 (en)
ES (2) ES2665466T3 (en)
WO (6) WO2011103470A1 (en)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2408207A (en) * 2003-11-24 2005-05-25 Johnson & Johnson Medical Ltd Wound dressing for the controlled release of therapeutic agents comprising also an inhibitor of a protease enzyme & a linker group cleavable by such an enzyme
CA2999420A1 (en) 2005-09-27 2007-04-05 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and methods of use
US8187639B2 (en) 2005-09-27 2012-05-29 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
US8372437B2 (en) 2006-08-17 2013-02-12 Mimedx Group, Inc. Placental tissue grafts
DE102007007664B3 (en) 2007-02-13 2008-03-27 Mokveld Valves B.V. Throttle valve e.g. for undersea oil and gas supply, has permanent magnet on adjustment element to provide rotation of adjustment element
EP4559488A3 (en) 2007-09-07 2025-08-13 MiMedx Group, Inc. Placental tissue grafts and improved methods of preparing and using the same
US9301679B2 (en) 2007-11-01 2016-04-05 Dignity Health Method of detecting neurological disease
US9358320B2 (en) 2008-04-25 2016-06-07 Allosource Multi-layer tissue patches
US9480549B2 (en) 2008-04-25 2016-11-01 Allosource Multi-layer tissue patches
US9192695B2 (en) 2008-11-20 2015-11-24 Allosource Allografts combined with tissue derived stem cells for bone healing
US9205177B2 (en) 2009-03-04 2015-12-08 Peytant Solutions, Inc. Stents modified with material comprising amnion tissue and corresponding processes
CA2790436A1 (en) 2010-02-18 2011-08-25 Osiris Therapeutics, Inc. Immunocompatible chorionic membrane products
US8883210B1 (en) 2010-05-14 2014-11-11 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US9352003B1 (en) 2010-05-14 2016-05-31 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US20130156863A1 (en) * 2010-06-30 2013-06-20 Tissuetech, Inc. Methods of preparing chorion tissue and products derived therefrom
WO2012103470A2 (en) 2011-01-28 2012-08-02 Dignity Health Method of detecting neurological disease
KR20140114277A (en) * 2011-02-14 2014-09-26 미메딕스 그룹 인크. Laminated tissue grafts composed of wharton's jelly and methods of making and using the same
EP3311826B1 (en) 2011-02-14 2020-04-29 MiMedx Group, Inc. Micronized placental tissue compositions and methods for making and using the same
WO2012149486A1 (en) 2011-04-28 2012-11-01 Tissuetech, Inc. Methods of modulating bone remodeling
EP2717888B1 (en) 2011-06-10 2020-09-09 Tissuetech, Inc. Methods of processing fetal support tissues
US12290613B2 (en) 2011-10-06 2025-05-06 Mimedx Group, Inc. Micronized compositions composed of bone grafts and methods of making and using the same
US8932805B1 (en) 2011-10-31 2015-01-13 BioDlogics, LLC Birth tissue material and method of preparation
US9162011B2 (en) 2011-12-19 2015-10-20 Allosource Flowable matrix compositions and methods
WO2013096659A1 (en) * 2011-12-20 2013-06-27 Cook General Biotechnology Llc Methods and compositions for storage of animal cells
US9416410B2 (en) * 2012-02-14 2016-08-16 Genetics Development Corporation Cutoff point delta Ct. method for HER2 PCR testing in breast cancer
US20130236506A1 (en) * 2012-03-08 2013-09-12 AFcell Medical Amnion and chorion constructs and uses thereof in ob-gyn surgery
US8961617B2 (en) 2012-03-08 2015-02-24 Liventa Bioscience, Inc. Amnion and chorion constructs and uses thereof in abdominal surgery
CA2880157C (en) * 2012-08-15 2020-07-21 Mimedx Group, Inc. Reinforced placental tissue grafts and methods of making and using the same
US8904664B2 (en) 2012-08-15 2014-12-09 Mimedx Group, Inc. Dehydration device and methods for drying biological materials
US9943551B2 (en) * 2012-08-15 2018-04-17 Mimedx Group, Inc. Tissue grafts composed of micronized placental tissue and methods of making and using the same
EP2897625B1 (en) * 2012-09-10 2019-10-23 Wake Forest University Health Sciences Amniotic membrane and its use in wound healing and tissue engineering constructs
US9180145B2 (en) 2012-10-12 2015-11-10 Mimedx Group, Inc. Compositions and methods for recruiting and localizing stem cells
US9155799B2 (en) 2012-11-19 2015-10-13 Mimedx Group, Inc. Cross-linked collagen with at least one bound antimicrobial agent for in vivo release of the agent
US8946163B2 (en) 2012-11-19 2015-02-03 Mimedx Group, Inc. Cross-linked collagen comprising metallic anticancer agents
US9662355B2 (en) 2013-01-18 2017-05-30 Mimedx Group, Inc. Methods for treating cardiac conditions
US10206977B1 (en) * 2013-01-18 2019-02-19 Mimedx Group, Inc. Isolated placental stem cell recruiting factors
US9616093B2 (en) * 2013-01-30 2017-04-11 NuTech Medical, Inc. Placental membrane preparation and methods of making and using same
US20140212390A1 (en) * 2013-01-30 2014-07-31 NuTech Medical, Inc. Placental Membrane Preparation and Methods of Making and Using Same
WO2014120946A1 (en) * 2013-01-30 2014-08-07 NuTech Medical, Inc. Placental membrane preparation and methods of making and using same
US9770472B1 (en) * 2013-03-08 2017-09-26 Brahm Holdings, Llc Organ jacket and methods of use
US11077229B1 (en) 2013-03-08 2021-08-03 BioDlogics, LLC Implant coating composition and method of use
AU2014248873B2 (en) 2013-03-13 2017-03-23 Allosource Fascia fibrous compositions and methods for their use and manufacture
US10029030B2 (en) 2013-03-15 2018-07-24 Mimedx Group, Inc. Molded placental tissue compositions and methods of making and using the same
US20160379205A1 (en) 2013-03-15 2016-12-29 Apple Inc. Facilitating transactions with a user account using a wireless device
CA2899713C (en) 2013-03-15 2022-07-19 Allosource Cell repopulated collagen matrix for soft tissue repair and regeneration
US9993506B1 (en) 2013-03-16 2018-06-12 BioDlogics, Inc. Methods for the treatment of degenerative disc diseases by human birth tissue material composition
US10555897B1 (en) 2013-03-16 2020-02-11 Brahm Holdings Llc Cosmetic composition and methods of treatment
US9795639B1 (en) 2013-03-16 2017-10-24 BioDlogics, LLC Methods for the treatment of erectile dysfunction by human birth tissue material compostion
US10039792B1 (en) 2013-03-16 2018-08-07 Brahm Holdings, Llc Methods for the treatment of inflammation and pain using human birth tissue material composition
US9446142B2 (en) 2013-05-28 2016-09-20 Mimedx Group, Inc. Polymer chelator conjugates
EP3004328A4 (en) * 2013-05-30 2016-12-07 Cells For Cells Chorion-derived mscs cells and conditioned media as inducer for angiogenesis application for the treatment of cardiac degeneration.
JP6512759B2 (en) 2013-08-19 2019-05-15 国立研究開発法人国立循環器病研究センター Method of producing amniotic mesenchymal cell composition, method of cryopreservation, and therapeutic agent
JP6756612B2 (en) 2013-08-30 2020-09-16 ミメディクス グループ インコーポレイテッド Finely divided placental composition containing a chelator
CN104560862B (en) * 2013-10-14 2019-09-13 佛教慈济医疗财团法人 Method for separating adipose tissue living cells, medical composition, application of medical composition and cell bank
KR102161901B1 (en) 2013-12-06 2020-10-05 알로소스 Method of drying sheets of tissue
WO2015109329A1 (en) * 2014-01-17 2015-07-23 Mimedx Group, Inc. Method for inducing angiogenesis
US9856454B2 (en) 2014-02-27 2018-01-02 Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation Rapid mincing of adipose tissues to isolate live cells in vitro
AU2014393404A1 (en) * 2014-05-07 2016-11-24 Osiris Therapeutics, Inc. Immunocompatible amniotic membrane products
AU2014393403A1 (en) * 2014-05-07 2016-11-24 Osiris Therapeutics, Inc. Immunocompatible chorionic membrane products
JP2017514876A (en) * 2014-05-07 2017-06-08 オシリス セラピューティクス，インコーポレイテッド Therapeutic placenta composition, its production and use
TW201603818A (en) 2014-06-03 2016-02-01 組織科技股份有限公司 Composition and method
AU2015305371B2 (en) 2014-08-21 2019-11-21 Dignity Health Systems and methods for using eye movements to determine traumatic brain injury
JP7099822B2 (en) 2014-08-28 2022-07-12 ミメディクス グループ インコーポレイテッド Collagen-enhanced tissue graft
EP3193953B1 (en) 2014-09-19 2020-03-11 Osiris Therapeutics, Inc. Bone repair product and methods of use thereof
US12083245B2 (en) 2014-10-02 2024-09-10 Wake Forest University Health Sciences Amniotic membrane powder and its use in wound healing and tissue engineering constructs
US20160095307A1 (en) * 2014-10-07 2016-04-07 NuTech Medical, Inc. Method and composition for hypothermic storage of placental tissue
US10201573B1 (en) 2014-10-27 2019-02-12 Brahm Holdings, Llc Human birth tissue material composition and methods for the treatment of damage associated with a cerebral vascular accident
US10265438B1 (en) 2014-11-03 2019-04-23 BioDlogics, LLC Methods and compositions for the repair and replacement of connective tissue
US10765705B2 (en) 2014-11-24 2020-09-08 Prime Merger Sub, Llc Visco-supplement compositions, and methods of use thereof
US20160287750A1 (en) * 2014-12-31 2016-10-06 Applied Biologics, Llc Standardized amniotic membrane tissue graft
WO2016138025A2 (en) 2015-02-23 2016-09-01 Tissuetech, Inc. Apparatuses and methods for treating ophthalmic diseases and disorders
TWI720984B (en) 2015-05-20 2021-03-11 美商帝聖工業公司 Compositions and methods for preventing the proliferation and epithelial-mesenchymal transition of epithelial cells
WO2017025965A1 (en) * 2015-08-13 2017-02-16 Kamada Ltd. Compositions derived from cohn fraction paste and use thereof
US12551509B2 (en) 2015-11-18 2026-02-17 Lucina Patent Holdco, Llc Acellular regenerative products and methods of their manufacture
WO2017112934A1 (en) * 2015-12-23 2017-06-29 Lifenet Health Decellularized placental membrane and methods of preparing and use thereof
AU2017206020B2 (en) 2016-01-08 2021-07-08 Cryolife, Inc. Human placental tissue graft products, methods, and apparatuses
TW201733600A (en) 2016-01-29 2017-10-01 帝聖工業公司 Fetal support tissue products and methods of use
DK3429689T3 (en) * 2016-03-14 2022-01-31 Plakous Therapeutics Inc Acellular placental preparations
EP3474869B1 (en) 2016-06-24 2025-04-09 Osiris Therapeutics, Inc. Human tissue derived compositions and uses thereof
EP3474665A4 (en) * 2016-06-24 2020-01-01 Osiris Therapeutics, Inc. VIABLE LYOPHILIZED COMPOSITIONS OBTAINED FROM HUMAN TISSUES, AND METHODS OF MAKING SAME
WO2018002930A1 (en) 2016-06-30 2018-01-04 Stem Cell Medicine Ltd. Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
CA3032160C (en) 2016-08-24 2024-05-28 Arthrex, Inc. Tissue hybrid for use in repairing, reconstructing or regenerating musculoskeletal degenerative processes or injuries
US10772986B2 (en) 2017-01-26 2020-09-15 Allosource Fascia fibrous compositions and methods for their use and manufacture
US10960028B2 (en) 2017-02-01 2021-03-30 Plakous Therapeutics, Inc. Placental tissue compositions
CN106834257B (en) * 2017-03-23 2020-06-30 天晴干细胞股份有限公司 Mixed enzyme for separating placenta mesenchymal stem cells and separation method thereof
EP3624815A4 (en) 2017-05-15 2021-01-20 Stem Cell Medicine Ltd. TREATMENT OF MULTIPLE SCLEROSIS WITH A LONG-ACTING GLATIRAMERA AND STEM CELLS DERIVED FROM THE FAT TISSUE
EP3624816A4 (en) 2017-05-15 2021-02-24 Stem Cell Medicine Ltd. TREATMENT OF MULTIPLE SCLEROSIS WITH ADAPTIVE STEM CELLS
CN107254431B (en) * 2017-05-25 2020-08-18 林翠霞 Novel tissue engineering skin preparation method
CN107296041B (en) * 2017-07-02 2020-12-25 江西瑞济生物工程技术股份有限公司 Fresh amnion preservation solution, fresh amnion preservation method and application
GB2582521B (en) 2017-11-14 2022-07-13 Cook Biotech Inc Preserved tissue products and related methods
CN107779429A (en) * 2017-12-07 2018-03-09 陕西九州生物医药科技集团有限公司 A kind of tissue-derived fibroblast quick separating cultural method of application on human skin
CN109652363A (en) * 2018-11-13 2019-04-19 广东唯泰生物科技有限公司 Placenta decidua vera Derived from Mesenchymal Stem Cells is the method for endometrial epithelial cell
WO2020131717A1 (en) * 2018-12-16 2020-06-25 Figene, Llc Therapeutic uses of gene edited fibroblasts
US11511017B2 (en) 2019-03-12 2022-11-29 Arthrex, Inc. Ligament reconstruction
CA3135546A1 (en) * 2019-04-04 2020-10-08 THT Biomaterials GmbH A novel human-material-based platform technology for tissue engineering
CN110144322A (en) * 2019-04-15 2019-08-20 湖南南华爱世普林生物技术有限公司 A method for rapid isolation and culture of placental mesenchymal stem cells until harvest and cryopreservation
JP7684908B2 (en) * 2019-04-16 2025-05-28 ライフネット ヘルス Birthing tissue derived products and their preparation and use
CN110141686B (en) * 2019-05-07 2021-11-02 吉林省海创生物科技有限公司 Human umbilical cord mesenchymal stem cell injection and facial filling injection method thereof
CN110179679A (en) * 2019-06-25 2019-08-30 贵州医科大学 The biological beauty treatment Face-protecting mask essence of the liquid extract of culture containing umbilical cord mesenchymal stem cells, facial mask and preparation method thereof
WO2021003257A1 (en) * 2019-07-01 2021-01-07 Auxocell Laboratories, Inc. Methods and compositions for collecting and using placental tissue cells and placental blood cells
WO2021123320A1 (en) * 2019-12-20 2021-06-24 Dr. Kalali Prof. Mostafazadeh Dipl. Ing. Miedl (Kmm) Gesellschaft Bürgerlichen Rechts A composition and its use for a universal therapy against tumor cells
WO2021183851A1 (en) * 2020-03-12 2021-09-16 Osiris Therapeutics, Inc. Human tissue derived compositions and uses thereof
WO2022074523A1 (en) 2020-10-06 2022-04-14 Osiris Therapeutics, Inc. Primed placental tissue and uses in regenerative medicine
US20230301786A1 (en) 2020-11-06 2023-09-28 Smith & Nephew, Inc. Graft composite for hip labrum reconstruction
TW202245598A (en) * 2021-02-09 2022-12-01 美商千禧製藥公司 Methods and compositions for freezing and thawing mammalian cells
KR102523933B1 (en) * 2021-05-03 2023-04-20 고려대학교 산학협력단 Pharmaceutical composition for stimulating bone formation comprising exosomes isolated from chorion membrane extract
WO2023150544A1 (en) * 2022-02-01 2023-08-10 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Simplified method of preparing cells for patient administration
US12594363B2 (en) * 2022-03-01 2026-04-07 XoBiologix, L.L.C. Enhanced biologic grafts with packaging apparatuses, and methods of use
WO2024020135A1 (en) * 2022-07-21 2024-01-25 Biostem Technologies, Inc. Collection and quantification of elements per square centimeter in a human placental membrane allograft

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8803697D0 (en) 1988-02-17 1988-03-16 Deltanine Research Ltd Clinical developments using amniotic membrane cells
US5891617A (en) * 1993-09-15 1999-04-06 Organogenesis Inc. Cryopreservation of harvested skin and cultured skin or cornea equivalents by slow freezing
US6152142A (en) * 1997-02-28 2000-11-28 Tseng; Scheffer C. G. Grafts made from amniotic membrane; methods of separating, preserving, and using such grafts in surgeries
AU2005202256B2 (en) * 1999-11-05 2008-04-03 Gerigene Medical Corporation Augmentation and repair of age-related soft tissue defects
EP2335634A1 (en) 2000-02-11 2011-06-22 The General Hospital Corporation Photochemical tissue bonding
US7582292B2 (en) * 2000-02-26 2009-09-01 Artecel, Inc. Adipose tissue derived stromal cells for the treatment of neurological disorders
US20020039788A1 (en) 2000-02-29 2002-04-04 Isseroff Roslyn R. Corneal epithelial graft composites
US7504374B2 (en) * 2000-10-24 2009-03-17 Warsaw Orthopedic, Inc. Method for inducing deposition and maturation of bone comprising a co-therapeutic regimen of LMP-1 and BMP-2
US20080152629A1 (en) 2000-12-06 2008-06-26 James Edinger Placental stem cell populations
EP2316919B1 (en) * 2001-02-14 2015-10-07 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
EP3246396B1 (en) 2001-02-14 2020-01-29 Celularity, Inc. Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells
CN101979095A (en) * 2001-05-02 2011-02-23 普渡研究基金会 Treatment and diagnosis of macrophage-mediated diseases
EP1442115B9 (en) * 2001-11-15 2009-12-16 Children's Medical Center Corporation Methods of isolation, expansion and differentiation of fetal stem cells from chorionic villus, amniotic fluid, and placenta and therapeutic uses thereof
US20070134261A1 (en) * 2001-12-03 2007-06-14 Hancock Robert E Effectors of innate immunity
US20030187515A1 (en) 2002-03-26 2003-10-02 Hariri Robert J. Collagen biofabric and methods of preparing and using the collagen biofabric
CA2483010A1 (en) * 2002-04-19 2003-10-30 University Of Pittsburgh Of The Commonwealth System Of Higher Education Placental derived stem cells and uses thereof
EP1549347A1 (en) * 2002-10-09 2005-07-06 Lorantis Limited Modulation of immune function
US7993922B2 (en) * 2002-10-18 2011-08-09 Reliance Life Sciences Pvt. Ltd. Three-dimensional tissue equivalent using macromass culture
WO2005007835A1 (en) * 2003-06-16 2005-01-27 Zephan Biopharmaceuticals, Inc. Methods of preparing a transplantable product for treatment of skin defects
WO2006071794A2 (en) * 2004-12-23 2006-07-06 Ethicon Incorporated Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
WO2005001080A2 (en) * 2003-06-27 2005-01-06 Ethicon, Incorporated Postpartum-derived cells for use in treatment of disease of the heart and circulatory system
WO2005021014A1 (en) 2003-09-03 2005-03-10 Jiuchang Miao Preparation of biological amnion preservable at room temperature
GB2408207A (en) 2003-11-24 2005-05-25 Johnson & Johnson Medical Ltd Wound dressing for the controlled release of therapeutic agents comprising also an inhibitor of a protease enzyme & a linker group cleavable by such an enzyme
US20050176139A1 (en) 2004-01-12 2005-08-11 Yao-Chang Chen Placental stem cell and methods thereof
US7244444B2 (en) * 2004-03-31 2007-07-17 Cook Incorporated Graft material, stent graft and method
US7280326B2 (en) * 2004-07-30 2007-10-09 Hitachi Global Storage Technologies Netherlands B.V. Trilayer SAF with current confining layer
PL369552A1 (en) 2004-08-12 2006-02-20 Sgp & Sons Ab Pharmaceutical or/and nutrient or/and laboratory preparation for increasing, supporting the functioning of nerve cells and nervous system as well as application of pharmaceutical or/and nutrient or/and laboratory preparation in protection of the functions
US20060111778A1 (en) 2004-10-29 2006-05-25 Michalow Alexander E Methods of promoting healing of cartilage defects and method of causing stem cells to differentiate by the articular chondrocyte pathway
US20080213332A1 (en) * 2004-11-10 2008-09-04 Shimon Slavin Cells Isolated from Placenta, Device for Isolating Same, and Uses Thereof
WO2006088867A2 (en) * 2005-02-15 2006-08-24 Medistem Laboratories, Incorporated Method for expansion of stem cells
WO2006094247A2 (en) * 2005-03-02 2006-09-08 Tissuetech, Inc. Amniotic membrane extracts, compositions thereof, and methods of use
US20070015278A1 (en) * 2005-04-13 2007-01-18 Yuling Li Methods of isolating differentiable cells from placental-associated tissue and uses thereof
US7928280B2 (en) 2005-07-13 2011-04-19 Anthrogenesis Corporation Treatment of leg ulcers using placenta derived collagen biofabric
WO2007011693A2 (en) * 2005-07-14 2007-01-25 Medistem Laboratories, Inc. Compositions of placentally-derived stem cells for the treatment of cancer
GB0514567D0 (en) 2005-07-15 2005-08-24 Univ Nottingham Surgical membrane
WO2007023750A1 (en) 2005-08-26 2007-03-01 National University Corporation University Of Toyama Dried amnion and method for drying treatment of amnion
CA2999420A1 (en) * 2005-09-27 2007-04-05 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and methods of use
CN101326281A (en) * 2005-10-13 2008-12-17 人类起源公司 Preparation of oligodendrocytes from placenta-derived stem cells
PT2471904T (en) 2005-12-29 2019-02-25 Celularity Inc Placental stem cell populations
CN101389754A (en) * 2005-12-29 2009-03-18 人类起源公司 Co-cultivation of placental stem cells and stem cells from a second source
US8871198B2 (en) * 2006-03-29 2014-10-28 Stemnion, Inc. Methods related to wound healing
US20070178159A1 (en) * 2006-01-30 2007-08-02 Alza Corporation In-Situ Forming Porous Scaffold
US20080064098A1 (en) * 2006-06-05 2008-03-13 Cryo-Cell International, Inc. Procurement, isolation and cryopreservation of maternal placental cells
CN101501185A (en) * 2006-06-09 2009-08-05 人类起源公司 Placental niche and use thereof to culture stem cells
WO2008021391A1 (en) * 2006-08-15 2008-02-21 Anthrogenesis Corporation Umbilical cord biomaterial for medical use
US8372437B2 (en) * 2006-08-17 2013-02-12 Mimedx Group, Inc. Placental tissue grafts
US20080131522A1 (en) * 2006-10-03 2008-06-05 Qing Liu Use of placental biomaterial for ocular surgery
WO2008060377A2 (en) 2006-10-04 2008-05-22 Anthrogenesis Corporation Placental or umbilical cord tissue compositions
JP5484059B2 (en) * 2006-10-06 2014-05-07 エスシーアイエル テクノロジー ゲゼルシャフト ミット ベシュレンクテル ハフツング Spinal nucleus implant
KR20230146124A (en) * 2006-10-06 2023-10-18 셀룰래리티 인코포레이티드 Native(telopeptide) Placental Collagen Compositions
ZA200902233B (en) 2006-10-23 2010-07-28 Anthrogenesis Corp Methods and compositions for treatment of bone defects with placental cell populations
EP3763376A1 (en) * 2007-02-12 2021-01-13 Celularity, Inc. Treatment of inflammatory diseases using placental stem cells
EP2133105A4 (en) 2007-02-23 2012-12-19 Nat Univ Corp Univ Toyama MEDICAL REPLACEMENT MEMBRANE, USE THEREOF, AND METHOD FOR REPAIRING MEMBRANE TISSUE IN LIVING BODY
KR20080104844A (en) * 2007-05-29 2008-12-03 포천중문의과대학교 산학협력단 Isolation of Placental-derived Trophoblast Stem Cells
EP2014767A1 (en) * 2007-06-15 2009-01-14 Centro di Ricerca E. Menni T cell immunomodulation by placenta cell preparations
EP2164953A4 (en) * 2007-06-18 2010-06-30 Childrens Hosp & Res Ct Oak METHOD FOR ISOLATING PLACENTA FROM STEM AND PROGENITOR CELLS
EP2182971B1 (en) * 2007-07-27 2013-12-18 Humacyte, Inc. Compositions comprising human collagen and human elastin and uses thereof
CA2700613C (en) * 2007-09-26 2022-09-20 Celgene Cellular Therapeutics Angiogenic cells from human placental perfusate
NZ599825A (en) * 2007-09-28 2014-10-31 Anthrogenesis Corp Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
WO2009044408A1 (en) 2007-10-03 2009-04-09 International Centre For Cardio Thoracic And Vascular Diseases (A Unit Of Frontier Lifeline Pvt. Ltd) A treated amniotic membrane and method of treating amniotic membrane
BRPI0821489A2 (en) * 2007-12-27 2015-06-16 Ethicon Inc Treatment of intervetebral disc degeneration using cells derived from human umbilical cord tissue
EP2271208A1 (en) 2008-03-27 2011-01-12 Biolife Solutions, Inc. Mehtod, system, and apparatus for hypothermic collection, storage, transport and banking of birth tissue
US20110129520A1 (en) 2008-04-25 2011-06-02 Simon Bogdansky Anti-Adhesion Barrier Wound Dressing Comprising Processed Amniotic Tissue and Method of Use
WO2010021715A1 (en) * 2008-08-20 2010-02-25 Anthrogenesis Corporation Treatment of stroke using isolated placental cells
WO2011074208A1 (en) 2009-12-18 2011-06-23 国立大学法人東北大学 Method for preparation of corneal transplantation material by transparentization of skin dermis or amnion
US20150010506A1 (en) 2010-02-18 2015-01-08 Osiris Therapeutics, Inc. Therapeutic placental compositions, methods of making and methods of use
US20150010610A1 (en) 2010-02-18 2015-01-08 Osiris Therapeutics, Inc. Immunocompatible amniotic membrane products
US20150010609A1 (en) 2010-02-18 2015-01-08 Osiris Therapeutics, Inc. Immunocompatible chorionic membrane products
CA2790436A1 (en) 2010-02-18 2011-08-25 Osiris Therapeutics, Inc. Immunocompatible chorionic membrane products
US8632512B2 (en) 2010-04-09 2014-01-21 Kci Licensing, Inc. Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds
JP2014115445A (en) 2012-12-10 2014-06-26 Funai Electric Co Ltd Optical device
AU2014393404A1 (en) 2014-05-07 2016-11-24 Osiris Therapeutics, Inc. Immunocompatible amniotic membrane products
JP2017514876A (en) 2014-05-07 2017-06-08 オシリス セラピューティクス，インコーポレイテッド Therapeutic placenta composition, its production and use
AU2014393403A1 (en) 2014-05-07 2016-11-24 Osiris Therapeutics, Inc. Immunocompatible chorionic membrane products

Also Published As

Publication number Publication date
EP2536825B1 (en) 2024-03-27
US20140127317A1 (en) 2014-05-08
US12109241B2 (en) 2024-10-08
US20110212158A1 (en) 2011-09-01
WO2011103470A1 (en) 2011-08-25
AR080218A1 (en) 2012-03-21
US11207353B2 (en) 2021-12-28
EP2536417B1 (en) 2018-01-10
US10265344B2 (en) 2019-04-23
US10258650B2 (en) 2019-04-16
US10576104B2 (en) 2020-03-03
US20140301986A1 (en) 2014-10-09
CA2790436A1 (en) 2011-08-25
US9956248B2 (en) 2018-05-01
US20140037598A1 (en) 2014-02-06
EP2536825A1 (en) 2012-12-26
EP2536823A1 (en) 2012-12-26
US20240189361A1 (en) 2024-06-13
EP2536823B1 (en) 2017-12-20
US20110212064A1 (en) 2011-09-01
US11638725B2 (en) 2023-05-02
EP2536824A4 (en) 2014-04-30
EP3351624B1 (en) 2022-09-14
US20230381241A1 (en) 2023-11-30
CA2790322A1 (en) 2011-08-25
US20140140966A1 (en) 2014-05-22
AR080220A1 (en) 2012-03-21
US20200230176A1 (en) 2020-07-23
WO2011103462A1 (en) 2011-08-25
US20110212065A1 (en) 2011-09-01
US12318408B2 (en) 2025-06-03
EP3345998A1 (en) 2018-07-11
EP2536827A4 (en) 2014-06-11
WO2011103451A1 (en) 2011-08-25
EP2536825A4 (en) 2014-05-07
US20110212063A1 (en) 2011-09-01
AR080223A1 (en) 2012-03-21
US20200069739A1 (en) 2020-03-05
US20110256202A1 (en) 2011-10-20
EP2536826A4 (en) 2014-05-14
CA2790333A1 (en) 2011-08-25
US20240050482A1 (en) 2024-02-15
US20240261335A1 (en) 2024-08-08
US11590172B2 (en) 2023-02-28
US11986498B2 (en) 2024-05-21
WO2011103455A1 (en) 2011-08-25
EP2536827A1 (en) 2012-12-26
ES2665466T3 (en) 2018-04-25
EP2536824A1 (en) 2012-12-26
EP3351622A1 (en) 2018-07-25
US20200330520A1 (en) 2020-10-22
US20140127177A1 (en) 2014-05-08
ES2663720T3 (en) 2018-04-16
US20210369784A1 (en) 2021-12-02
CA2790325A1 (en) 2011-08-25
CA2790336A1 (en) 2011-08-25
EP2536417A1 (en) 2012-12-26
EP2536826B1 (en) 2020-12-16
CA2790340A1 (en) 2011-08-25
EP3345998B1 (en) 2024-08-14
WO2011103446A1 (en) 2011-08-25
US10646519B2 (en) 2020-05-12
EP2536417A4 (en) 2014-05-07
US11590173B2 (en) 2023-02-28
EP2536824B1 (en) 2018-04-04
US20180360886A1 (en) 2018-12-20
US20250064857A1 (en) 2025-02-27
EP3351622B1 (en) 2022-01-19
US11510947B2 (en) 2022-11-29
US20240189362A1 (en) 2024-06-13
WO2011103472A1 (en) 2011-08-25
EP3351624A1 (en) 2018-07-25
US20250262245A1 (en) 2025-08-21
US20110206776A1 (en) 2011-08-25
EP2536823A4 (en) 2014-04-30
US20200281981A1 (en) 2020-09-10
US10272116B2 (en) 2019-04-30
EP2536826A1 (en) 2012-12-26
CA3175739A1 (en) 2011-08-25
AR080219A1 (en) 2012-03-21
US20200000853A1 (en) 2020-01-02
EP2536827B1 (en) 2018-01-10
US12558377B2 (en) 2026-02-24
AR080222A1 (en) 2012-03-21
US20140294777A1 (en) 2014-10-02
EP3351625A1 (en) 2018-07-25
US20230128936A1 (en) 2023-04-27
US20230113145A1 (en) 2023-04-13

Similar Documents

Publication Publication Date Title
AR080221A1 (en) IMMUNOCOMPATIBLE AMNIOTIC MEMBRANE PRODUCTS
Salama et al. Female fertility loss and preservation: threats and opportunities
Bedaiwy et al. Reproductive organ transplantation: advances and controversies
WO2015031654A3 (en) Systems, compositions, and methods for transplantation and treating conditions
WO2020223125A8 (en) Composition and method for cryopreservation of cells
JP6745449B2 (en) Umbilical cord tissue cryopreservation method
KR101407355B1 (en) A composition for cryopreservation of stem cells or primary cells comprising plant-derived human serum albumin, plant protein hydrolysate and lipid
WO2010096821A3 (en) Method for ice-free cryopreservation of tissue
RU2015154110A (en) TRAGALOSE AND DEXTRAN-CONTAINING SOLUTION FOR TRANSPLANTATION OF MAMMAL CELLS
WO2014051173A1 (en) Composition comprising plant-derived recombinant human serum albumin, lipids, and plant protein hydrolysates as active ingredients for cryopreservation of stem cells or primary cells
Seo et al. Cryopreservation of amniotic fluid-derived stem cells using natural cryoprotectants and low concentrations of dimethylsulfoxide
CN103704206B (en) placenta preservation solution
GB2514506A (en) Critical point drying systems and methods for in situ tissue preservation
MX2015014386A (en) Improving organs for transplantation.
CN109362708A (en) A kind of stem cell cryogen and its application
WO2021031614A1 (en) Human oocyte cryoprotectant having highly efficient anti-oxidation
Chu et al. The mechanism and protective strategies of follicle injury after ovarian tissue cryopreservation and thawed transplantation: a review
KR20150101498A (en) Composition for cryopreservating boer sperm comprising astaxanthin or curcumin
CN112075417B (en) A kind of adipose mesenchymal stem cell cryopreservation solution and cryopreservation method thereof
CN102580152A (en) Method for preparing acellular bone
Isachenko et al. Cryopreservation of whole ovine ovaries with pedicles as a model for human: parameters of perfusion with simultaneous saturations by cryoprotectants
US20210315199A1 (en) Cryopreservation medium for umbilical cord mscs derived from wharton's jelly
Papis A brief overview of the development of oocyte and embryo cryopreservation strategies with a focus on the roles of sugars
MX2021012141A (en) COMPOSITION FOR TISSUE REGENERATION, PRODUCTION METHOD AND USES THEREOF.
Restrepo B et al. Antioxidant activity of isoespintanol and thymol in cryopreserved stallion semen.

Legal Events

Date Code Title Description
FB Suspension of granting procedure